Comparative Clinical Pathology

, Volume 28, Issue 4, pp 1013–1024 | Cite as

Pathogenicity of Cryptococcus neoformans VNI (ST 32) recovered from environmental and clinical isolates in Nigeria

  • Chidebelu Paul
  • Nweze EmekaEmail author
Original Article


We present the comparative pathogenicity of Nigeria environmental and clinical Cryptococcus neoformans VNI (ST32) strains in an animal model. Isolates previously identified and confirmed in a different study, using matrix-assisted laser desorption ionization–time-of-flight mass spectrometry (MALDI–TOF MS) and multi-locus sequence typing (MLST) techniques, were inoculated into male mice weighing 26 ± 4.0 g. Postinfection survival time, tissue fungal burden, and histopathological changes were observed. Log–rank survival curve comparisons showed that there is a significant difference between clinical and control isolates and between environmental and control isolates. However, when intragroup and intergroup comparisons were made, no significant difference was observed. There was a significant difference when the brain fungal burden of mice infected with environmental isolate was compared with the kidney fungal burden. Tissues of the control group inoculated with PBS showed no evidence of lesions. The mouse group infected with clinical isolates showed a significant difference when the brain fungal burden was compared with the kidney fungal burden. No lesion was produced in the kidneys of mouse groups infected with environmental and positive control isolates. The evaluated pathogenicity indices in this study may suggest that both the environmental and clinical isolates of C. neoformans VNI exhibit similar pathogenicity potential.


Cryptococcus neoformans Pathogenicity Nigeria Fungal burden Clinical Environmental 



We express our profound gratitude to our kind collaborators, Dr. Ferry Hagen and Prof. JF Meis, both of the Department of Medical Microbiology and Infectious Diseases, Wilhelmina Ziekenhuis, Nijmegen, The Netherlands, for the confirmation (using molecular tools) of the experimental cryptococcal strains used in this study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.


  1. Becker GJ, Hewitson TD (2013) Animal models of chronic kidney disease: useful but not perfect. Nephrol Dial Transplant 28:2432–2438CrossRefPubMedGoogle Scholar
  2. Bicanic T, Brouwer AE, Meintjes G, Rebe K, Limmathurotsakul D, Chierakul W, Teparrakkul P, Loyse A, White NJ, Wood R, Jaffar S, Harrison T (2009) Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 23(6):701–706PubMedGoogle Scholar
  3. Casadevall A, Profski L (2013) Exserohilum rostratum fungal meningitis associated with methylprednisolone injections. Future Microbiol 8(2):135–137CrossRefPubMedPubMedCentralGoogle Scholar
  4. Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenbery KK, Kwon-Chung KJ (2008) Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis 14(5):755–762CrossRefPubMedPubMedCentralGoogle Scholar
  5. Chen SA, Yan HB, Zhang LB, Kong WB, Sun YB, Chen YB, Deng AB (2015) Cryptococcus neoformans infection and immune cell regulation in human monocytes. Cell Physiol Biochem 37:537–547CrossRefPubMedGoogle Scholar
  6. Chretien F, Lortholary O, Kansau I, Neuville S, Gray F, Dromer F (2002) Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis 186(4):522–530CrossRefPubMedGoogle Scholar
  7. Cianciolo RE, Rhodes JL, Haskins ME, Clubb FJ, Lees GE (2011) Renal failure associated with mucopolysaccharidosis type I in a cat from a MPSI research colony. Comp Med 61(5):44–444Google Scholar
  8. Clancy JC, Nguyen HM, Alandoerffer R, Cheng S, Kzkowski K, Richardson M, Graybill RJ (2006) Cryptococcus neoformans var. grubii isolates recovered from persons with AIDS demonstrate a wide range of virulence during murine meningoencephalitis that correlates with the expression of certain virulence factors. Microbiology 152:2247–2255CrossRefPubMedGoogle Scholar
  9. Coelho C, Bocca AL, Cassadevall A (2014) The intracellular life of Cryptococcus neoformans. Annu Rev Pathol 9:219–238CrossRefPubMedGoogle Scholar
  10. Daher EF, Nasserala JL, SilvaJunior GB, Oliveira AR, Medeiros Neto JU, Sousa AQ (2015) Fatal disseminated cryptococcosis with renal involvement in an HIV-infected patient. Rev Inst Med Trop Sao Paulo 57(4):365–367CrossRefPubMedCentralGoogle Scholar
  11. De Jesus M, Park CG, Su Y, Goldman DL, Steinman RM, Casadevall A (2008) Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C – type lectin SIGN – RI. Med Mycol 46(2):62153–62162CrossRefGoogle Scholar
  12. Dzoyem JP, Kechia FA, Ngaba GP, Lunga PK, Lohoue PJ (2012) Prevalence of cryptococcosis among HIV-infected patients in Yaounde Cameroon. Afr Health Sci 12(2):129–133CrossRefPubMedPubMedCentralGoogle Scholar
  13. Fries CB, Casadevall A (1998) Serial isolates of Cryptococcus neoformans from patients with AIDS differ in virulence for mice. J Infect Dis 178(6):1761–1766CrossRefPubMedGoogle Scholar
  14. Fries BC, Goodman DL, Cherniak R, Ju R, Casadevall A (1999) Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure. Infect Immun 67(11):6076–6083PubMedPubMedCentralGoogle Scholar
  15. Gibson JF, Johnston SA (2015) Immunity to Cryptococcus neoformans and C. gattii during cryptococcosis. Fungal Genet Biol 78:76–86CrossRefPubMedPubMedCentralGoogle Scholar
  16. Grammas P, Martinez J, Miller B (2011) Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med 13:e19. CrossRefPubMedGoogle Scholar
  17. Hu G, Chen HS, Qui J, Bennett EJ, Myers GT, Williamson RP (2014) Microevolution during serial mouse passage demonstrates FRE 3 as a virulence adaptation gene in Cryptococcus neoformans. mBio 5(2):200941–200914CrossRefGoogle Scholar
  18. Jain N, Li L, McFadden DC, Banarjee U, Wang X, Cook E, Fries BC (2006) Phenotypic switching in a Cryptococcus variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous. Infect Immun 74(2):896–903CrossRefPubMedPubMedCentralGoogle Scholar
  19. Kharsany AB, Karim QA (2016) HIV infection and AIDS in sub Saharan Africa: current status, challenges and opportunities. Open AIDS J 10:34–48CrossRefPubMedPubMedCentralGoogle Scholar
  20. Kwon-Chung KJ, Fraser JA, Doering TL, Wang Z, Janbon G, Idnurm A, Bahn Y (2014) Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med 4(7):a019760CrossRefPubMedPubMedCentralGoogle Scholar
  21. Silverman J, Lidz CW, Clayfield JC, Murray A, Simon LJ, Rondeau RG (2015) Decision making and the IACUC: part 1—protocol information discussed at full. J Am Assoc Lab Anim Sci 54(4):389–398PubMedPubMedCentralGoogle Scholar
  22. Lin Y-Y, Shiau S, Fang CT (2015) Risk factors for invasive Cryptococcus neoformans diseases: a case-control study. PLoS One 10(3):e0119090CrossRefPubMedPubMedCentralGoogle Scholar
  23. Litvintseva AP, Mitchell TG (2009) Most environmental isolates of Cryptococcus neoformans var. grubii (serotype A) are not lethal for mice. Infect Immun 77:3188–3195CrossRefPubMedPubMedCentralGoogle Scholar
  24. Liu TB, Perlin D, Xue C (2012) Molecular mechanisms of cryptococcal meningitis. Virulence 3(2):173–181CrossRefPubMedPubMedCentralGoogle Scholar
  25. Longley N, Harrison TS, Jarvis JN (2013) Cryptococcal immune reconstitution inflammatory syndrome. Curr Opin Infect Dis 26(1):26–34CrossRefPubMedGoogle Scholar
  26. Malakoutian T, Yarmohamadi M, Mohammadi R, Asgari M, Mahmoodian R (2016) Splenic abscess due to fungal infection after kidney transplantation; a case report. J Renal Inj Prev 5(3):168–170CrossRefPubMedPubMedCentralGoogle Scholar
  27. Maziarz EK, Perfect JR (2016) Cryptococcosis. Dis Clin North Am 30(1):179–206CrossRefGoogle Scholar
  28. Movahed E, Munusamy K, Tan GMY, Looi CY, Tay ST, Wong WF (2015) Genome-wide transcription study of Cryptococcus neoformans H99 clinical strains versus environmental strains. PLoS One 10(9):e0137457CrossRefPubMedPubMedCentralGoogle Scholar
  29. Ngamskulrungroj P, Chang Y, Sionov E, Kwon–Chung KJ (2012) The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model. mBio 3(3):e00103–e00112CrossRefPubMedPubMedCentralGoogle Scholar
  30. Nweze EI, Okafor JI (2010) Comparative virulence of Scedosporium species in animal models. Braz J Infect Dis 14(3):271–276CrossRefPubMedGoogle Scholar
  31. Parikh V, Tucci V, Galwankar S (2013) Infections of the nervous system. Int J Crit Illn Inj Sci 3(1):82–97Google Scholar
  32. Pedroso SR, Lavrador AM, Ferreira CJ, Candido CR, Maffer MC (2010) Cryptococcus neoformans var. grubii pathogenicity of environmental isolates correlate to virulence factors, susceptibility to fluconazole and molecular profile. Mem Inst Oswaldo Cruz 105(8):993–1000CrossRefPubMedGoogle Scholar
  33. Perry C, Chung J-Y, Ylaya K, Choi CH, Simpson A, Matsumoto KT and Hewitt SM (2016) A buffered Alcohol – Based Fixative for Histomorphologic and Molecular Applications. Journal of Histochemistry and Cytochemistry, 64 (7): 425–440Google Scholar
  34. Pongmekin P, Chongtrakool P, Santanirand P, Kiertiburanakul S (2014) Clinical characteristics and mortality risk factors of cryptococcal infection among HIV-negative patients. J Med Assoc Thail 197(1):36–43Google Scholar
  35. Robertson EJ, Najjuka G, Rolfes MA, Akampurisa A, Jain N, Anantharanjit, von Hoherberg M, Tassieri M, Carlsson A, Meya DB, Harrison TS, Fries BC, Boulware DR, Bicanic T (2014) Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis 209:74–82CrossRefPubMedGoogle Scholar
  36. Silva EG, Baroni FA, Viani FC, Ruiz LS, Gandra RF, Auler ME, Dias AL, Gambale W, Paula CR (2006) Virulence profile of strains of Cryptococcus neoformans var. grubii evaluated by experimental infection in BALB/C mice and correlation with exoenzyme activity. J Med Microbiol 55:139–142CrossRefPubMedGoogle Scholar
  37. Templeton SP, Buskirik AD, Green BJ, Beez-hold DH, Schemechel D (2010) Murine models of airway fungal exposure and allergic sensitization. Med Mycol 48(2):217–228CrossRefPubMedGoogle Scholar
  38. Velez N, Escandon P (2016) Distribution and association between environmental and clinical isolates of Cryptococcus neoformans in Bogota—Colombia, 2012–2015. Mem Inst Oswaldo Cruz 111(10):642–648Google Scholar
  39. Zhang B, Yu J, Liu L, Peng L, Chi F, Wu C, Jong A, Wang S, CaO H, Huang S (2015) Alpha 7 nicotinic acetylcholine receptor is required for blood/brain barrier injury-related CNS disorders caused by Cryptococcus neoformans and HIV-1 associated comorbidity factors. BMC Infect Dis 15:352CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of MicrobiologyUniversity of NigeriaNsukkaNigeria

Personalised recommendations